TY - JOUR
T1 - Structure-Based Design and Discovery of New M2 Receptor Agonists
AU - Fish, Inbar
AU - Stößel, Anne
AU - Eitel, Katrin
AU - Valant, Celine
AU - Albold, Sabine
AU - Huebner, Harald
AU - Möller, Dorothee
AU - Clark, Mary J.
AU - Sunahara, Roger K.
AU - Christopoulos, Arthur
AU - Shoichet, Brian K.
AU - Gmeiner, Peter
PY - 2017/11/22
Y1 - 2017/11/22
N2 - Muscarinic receptor agonists are characterized by apparently strict restraints on their tertiary or quaternary amine and their distance to an ester or related center. On the basis of the active state crystal structure of the muscarinic M2 receptor in complex with iperoxo, we explored potential agonists that lacked the highly conserved functionalities of previously known ligands. Using structure-guided pharmacophore design followed by docking, we found two agonists (compounds 3 and 17), out of 19 docked and synthesized compounds, that fit the receptor well and were predicted to form a hydrogen-bond conserved among known agonists. Structural optimization led to compound 28, which was 4-fold more potent than its parent 3. Fortified by the discovery of this new scaffold, we sought a broader range of chemotypes by docking 2.2 million fragments, which revealed another three micromolar agonists unrelated either to 28 or known muscarinics. Even pockets as tightly defined and as deeply studied as that of the muscarinic reveal opportunities for the structure-based design and the discovery of new chemotypes.
AB - Muscarinic receptor agonists are characterized by apparently strict restraints on their tertiary or quaternary amine and their distance to an ester or related center. On the basis of the active state crystal structure of the muscarinic M2 receptor in complex with iperoxo, we explored potential agonists that lacked the highly conserved functionalities of previously known ligands. Using structure-guided pharmacophore design followed by docking, we found two agonists (compounds 3 and 17), out of 19 docked and synthesized compounds, that fit the receptor well and were predicted to form a hydrogen-bond conserved among known agonists. Structural optimization led to compound 28, which was 4-fold more potent than its parent 3. Fortified by the discovery of this new scaffold, we sought a broader range of chemotypes by docking 2.2 million fragments, which revealed another three micromolar agonists unrelated either to 28 or known muscarinics. Even pockets as tightly defined and as deeply studied as that of the muscarinic reveal opportunities for the structure-based design and the discovery of new chemotypes.
UR - http://www.scopus.com/inward/record.url?scp=85035068873&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.7b01113
DO - 10.1021/acs.jmedchem.7b01113
M3 - Article
C2 - 29094937
AN - SCOPUS:85035068873
SN - 0022-2623
VL - 60
SP - 9239
EP - 9250
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 22
ER -